MannKind Corp. on Wednesday announced it is enrolling children ages 4 to 7 in an Afrezza safety study. Afrezza is an inhalable insulin powder used to treat diabetes in adults.

The Westlake Village biotech company said the study will monitor the effects of Afrezza in pediatric patients, assessing insulin levels, glucose changes and the short-term safety and tolerability of multiple doses of Afrezza.

“We are very pleased that we can extend the study to younger children who could benefit from the flexible dosing Afrezza provides and thankful for the families and investigators who have participated to date,” said Dr. David Kendall, chief medical officer of MannKind.

Shares of MannKind (MNKD) remained flat on Wednesday to close at $1.12 on the Nasdaq.